Fulminant Liver Failure after Treatment with a Checkpoint Inhibitor for Gastric Cancer: A Case Report and Review of the Literature

Keyphrases

• Fulminant Hepatic Failure 100%
• Checkpoint Inhibitors 100%
• Nivolumab 100%
• Gastric Cancer 100%
• Monoclonal Antibody 66%
• Hepatic Failure 66%
• Antibody Inhibition 66%
• Therapeutic Intervention 33%
• T Cells 33%
• Severe Liver Injury 33%
• Programmed Death-ligand 1 (PD-L1) 33%
• Docetaxel 33%
• Necrosis 33%
• Liver Biopsy 33%
• Liver Failure 33%
• Mechanical Ventilation 33%
• Hepatitis 33%
• Oxaliplatin 33%
• Progression-free Survival 33%
• Fluorouracil 33%
• Corticosteroids 33%
• Locally Advanced 33%
• Transaminitis 33%
• Status Epilepticus 33%
• Advanced Gastric Carcinoma 33%
• Checkpoint Inhibitor Therapy 33%
• Hepatic Damage 33%
• Plasma Exchange 33%
• Advanced Malignancies 33%
• Early Awareness 33%
• Pre-existing Liver Disease 33%

Medicine and Dentistry

• Liver Failure 100%
• Fulminant Hepatic Failure 100%
• Nivolumab 100%
• Abdominal Cancer 100%
• Liver Injury 66%
• Monoclonal Antibody 66%
• T Cell 33%
• Cancer 33%
• Awareness 33%
• Necrosis 33%
• Liver Disease 33%
• Artificial Respiration 33%
• Liver Biopsy 33%
• Elevated Transaminases 33%
• Oxaliplatin 33%
• Fluorouracil 33%
• Progression Free Survival 33%
• Status Epilepticus 33%
• Stomach Carcinoma 33%
• Plasma Exchange 33%
• Docetaxel 33%